References
2. Promislow DEL. A geroscience perspective on COVID-19 mortality. J Gerontol A Biol Sci Med Sci 2020;75:e30–e33.
3. Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 2020;116:1666–1687.
4. Pieralli F, Biondo B, Vannucchi V, et al. Performance of the CHA(2)DS(2)- VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia. Eur J Intern Med 2019;62:24–28. .
5. Yang HJ, Wang GJ, Shuai W, et al. The value of the CHADS(2) and CHA(2) DS(2)-VASc score for predicting the prognosis in lacunar stroke with or without atrial fibrillation patients. J Stroke Cerebrovasc Dis 2019;28: 1041–43.
6. Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in northern Italy. Eur Heart J 2020;41:1821–1829.
7. Gawałko M, Kapłon-Cieślicka A, Hohl M, et al. COVID-19 associated atrial fibrillation: incidence, putative mechanisms and potential clinical implications. IJC Heart Vasc 2020;30:100631.
8. Stone E, Kiat H, McLachlan CS. Atrial fibrillation in COVID-19: a review of possible mechanisms. FASEB J 2020;34:11347–11354.
9. Pardo Sanz A, Salido Tahoces L, Ortega Pérez R, et al. New-onset atrial fibrillation during COVID-19 infection predicts poor prognosis. Cardiol J 2021;28:34–40.
10. Romiti GF, Corica B, Lip GYH, et al. Prevalence and impact of atrial fibrillation in hospitalized patients with COVID-19: a systematic review and meta-analysis. J Clin Med 2021;10:2490.
11. Zuin M, Rigatelli G, Bilato C, et al. Pre-existing atrial fibrillation is associated with increased mortality in COVID-19 patients. J Interv Card Electrophysiol 2021;2:231–238.
12. Atkins JL, Masoli JAH, Delgado J, et al. Preexisting comorbidities predicting COVID-19 and mortality in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci 2020;75:2224–2230.
13. Chilimuri S, Sun H, Alemam A, et al. Predictors of mortality in adults admitted with COVID-19: retrospective cohort study from New York City. West J Emerg Med 2020;21:779–784.
14. Lanza GA, De Vita A, Ravenna SE, et al. Electrocardiographic findings at presentation and clinical outcome in patients with SARS-CoV-2 infection. Europace 2021;23:123–129.
15. Lovicu E, Faraone A, Fortini A. Admission Braden Scale score as an early independent predictor of in-hospital mortality among inpatients with COVID-19: a retrospective cohort study. Worldviews Evid Based Nurs 2021;18:247–253.
16. Quisi A, Alici G, Harbalioglu H, et al. The CHA2DS2-VASc score and in-hospital mortality in patients with COVID-19: a multicenter retrospective cohort study. Turk Kardiyol Dern Ars 2020;48:656–663.
17. Abacioglu OO, Yildirim A. The ATRIA score is superior to the m-CHA2DS2- Vasc score in predicting in-hospital mortality in COVID-19. Rev Assoc Med Bras 2021;67:443–448.
18. Aciksari G, Cetinkal G, Kocak M, et al. Evaluation of modified ATRIA risk score in predicting mortality in hospitalized patients with COVID-19. Am J Med Sci 2021;362:553–561.
19. Halalau A, Imam Z, Karabon P, et al. External validation of a clinical risk score to predict hospital admission and in-hospital mortality in COVID-19 patients. Ann Med 2021;53:78–86.
20. Uribarri A, Nunez-Gil IJ, Aparisi A, et al. Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry. Rev Esp Cardiol (Engl Ed) 2021; 74:608–615.
21. Caro-Codón J, Lip GYH, Rey JR, et al. Prediction of thromboembolic events and mortality by the CHADS2 and the CHA2DS2-VASc in COVID-19. Europace 2021;23:937–947.
22. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290:1049–1056.
23. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012;107:1172–1179.
24. Naccarelli GV, Panaccio MP, Cummins G, et al. CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients. Am J Cardiol 2012;109:1526–1533.
25. Moss TJ, Calland JM, Enfield KB, et al. New-onset atrial fibrillation in the critically ill. Crit Care Med 2017;45:790–797.
26. Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112:1142–1147.
27. Zuo H, Nygard O, Ueland PM, et al. Association of plasma neopterin with risk of an inpatient hospital diagnosis of atrial fibrillation: results from two prospective cohort studies. J Intern Med 2018;283:578–587.
28. Klouwenberg PMCK, Frencken JF, Kuipers S, et al. Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis. A cohort study. Am J Respir Crit Care Med 2017;195:205–211.
29. Kelesoglu S, Yilmaz Y, Ozkan E, et al. New onset atrial fibrilation and risk faktors in COVID-19. J Electrocardiol 2021;65:76–81.
30. Bosch NA, Cimini J, Walkey AJ. Atrial fibrillation in the ICU. Chest 2018; 154:1424–1434.
31. Li YG, Pastori D, Farcomeni A, et al. A simple clinical risk score (C(2) HEST) for predicting incident atrial fibrillation in Asian subjects: derivation in 471,446 Chinese subjects, with internal validation and external application in 451,199 Korean subjects. Chest 2019;155:510–518.
32. Hu WS, Lin CL. Comparison of CHA2DS2-VASc and C2HEST scores for predicting the incidence of atrial fibrillation among patients with end-stage renal disease. Perfusion 2020;35:842–846.
33. de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010;55:725–31.
34. Hsieh CY, Lee CH, Wu DP, et al. Prediction of new-onset atrial fibrillation after first-ever ischemic stroke: a comparison of CHADS 2, CHA 2 DS 2 -VASc and HATCH scores and the added value of stroke severity. Atherosclerosis 2018; 272:73–79.
35. Proietti M, Marzona I, Vannini T, et al. Long-term relationship between atrial fibrillation, multimorbidity and oral anticoagulant drug use. Mayo Clin Proc 2019;94:2427–2436.
36. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest 2010;137:263–272.